These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 32537818)

  • 1. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
    Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
    Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
    Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
    Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
    Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
    Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-κB signaling pathway.
    Islam SS; Al-Sharif I; Sultan A; Al-Mazrou A; Remmal A; Aboussekhra A
    Mol Carcinog; 2018 Mar; 57(3):333-346. PubMed ID: 29073729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
    Liu J; Chen X; Ward T; Pegram M; Shen K
    Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin (OPG) mediates the anti-carcinogenic effects of normal breast fibroblasts and targets cancer stem cells through inhibition of the β-catenin pathway.
    Alraouji NN; Hendrayani SF; Ghebeh H; Al-Mohanna FH; Aboussekhra A
    Cancer Lett; 2021 Nov; 520():374-384. PubMed ID: 34416336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
    Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ
    Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab inhibits IL-8 and the proangiogenic potential of triple negative breast cancer cells.
    Alraouji NN; Aboussekhra A
    Mol Carcinog; 2021 Jan; 60(1):51-59. PubMed ID: 33264466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
    Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
    J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab suppresses the pro-carcinogenic effects of breast cancer-associated fibroblasts through inhibition of the STAT3/AUF1 pathway.
    Al-Jomah N; Al-Mohanna FH; Aboussekhra A
    Carcinogenesis; 2021 Dec; 42(12):1439-1448. PubMed ID: 34718441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the β-catenin signaling pathway.
    Huang J; Yang B; Xiang T; Peng W; Qiu Z; Wan J; Zhang L; Li H; Li H; Ren G
    Mol Nutr Food Res; 2015 Jun; 59(6):1063-75. PubMed ID: 25755089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAC down-regulates estrogen receptor alpha and suppresses epithelial-to-mesenchymal transition in breast cancer cells.
    Al-Howail HA; Hakami HA; Al-Otaibi B; Al-Mazrou A; Daghestani MH; Al-Jammaz I; Al-Khalaf HH; Aboussekhra A
    BMC Cancer; 2016 Jul; 16():540. PubMed ID: 27465411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
    Jin K; Pandey NB; Popel AS
    Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
    Shrivastava S; Jeengar MK; Thummuri D; Koval A; Katanaev VL; Marepally S; Naidu VGM
    Biofactors; 2017 Mar; 43(2):152-169. PubMed ID: 27580587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression.
    Lin D; Kuang G; Wan J; Zhang X; Li H; Gong X; Li H
    Oncol Rep; 2017 Feb; 37(2):895-902. PubMed ID: 27959422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
    Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
    Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.
    Liu H; Yan R; Xiao Z; Huang X; Yao J; Liu J; An G; Ge Y
    Breast Cancer Res; 2023 Apr; 25(1):43. PubMed ID: 37069669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
    Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
    Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.